PTGX
Protagonist Therapeutics, Inc.
46.08
+
1.31
2.93%
1 x 45.93
1 x 46.26
bid
ask
12:48 PM
timesize
Bearish
4
Bullish
20
sentiment
45.39
day range
46.54
13.72
52 week range
48.00
Prev Close44.77
Open45.93
Low45.39
High46.54
Volume158.25K
Avg. Volume944.98K
Market Cap2.71B
Inst. Own102.43%
Beta2.17
Short Ratio5.27
Div & Yield0.00 /
EPS2.72
P/E16.94
1yr Target50.67
50day MA40.04
200day MA30.59
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | -0.61 | N/A | N/A | N/A |
2024-08-06 | 2024-06 | -0.5 | -0.5 | N/A | N/A |
2024-05-07 | 2024-03 | 2.51 | 3.26 | 0.75 | 29.88% |
2024-02-27 | 2023-12 | -0.16 | 0.44 | 0.6 | 375.00% |
2023-11-02 | 2023-09 | -0.68 | -0.58 | 0.1 | 14.71% |
2023-08-03 | 2023-06 | -0.65 | -0.68 | -0.03 | -4.62% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-09-24 | JP Morgan | Upgrade | Overweight | Overweight |
2023-08-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-05 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
2023-07-02 | Piper Sandler | Upgrade | Overweight | Overweight |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-09-10 | ALI ASIF | Chief Financial Officer | 34.96K | Sale |
2024-01-08 | GUPTA SUNEEL | Officer | 187.57K | Sale |
2022-02-14 | KALKOFEN DONALD A. | Chief Financial Officer | 18.52K | Stock Award(Grant) |
2022-11-15 | LIU DAVID Y. | Officer | 167.59K | Conversion of Exercise of derivative security |
2024-01-01 | MOLINA ARTURO MD | Officer | 48.78K | Stock Award(Grant) |
2021-02-10 | NOONBERG SARAH B | Director | 0.00 | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | RTW Investments LP | 5.42M | 149.58M | 9.41% |
2023-06-29 | Blackrock Inc. | 5.01M | 138.36M | 8.71% |
2023-06-29 | Farallon Capital Management Llc | 4.51M | 124.61M | 7.84% |
2023-06-29 | BVF Inc. | 3.78M | 104.29M | 6.56% |
2023-06-29 | State Street Corporation | 3.55M | 98.11M | 6.17% |
2023-06-29 | Vanguard Group Inc | 3.15M | 86.94M | 5.47% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.41M | 47.69M | 4.18% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.66M | 45.82M | 2.88% |
2023-08-30 | iShares Russell 2000 ETF | 1.24M | 24.67M | 2.16% |
2023-06-29 | Vanguard Extended Market Index Fund | 762.17K | 21.05M | 1.32% |
2023-07-30 | Fidelity Small Cap Index Fund | 484.77K | 9.40M | 0.84% |
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 459.21K | 9.10M | 0.80% |
This topic has been deleted. Only users with topic management privileges can see it.
-
$OCGN -buy today WHO approval this tues get in cheap while you can.
-
-
-
-
-
-
-
$PTGX volume cranked $49 today shorts trying hard too discourage …
-
Look at all the scared shorts trying too scare sells….lol classic.
-
$PTGX back in for run too $45…
-
$40 today
-
$PTGX Heading straight back too $45
-
Strong day in a sea of red
-
Parabolic trend incoming
-
Will halt today for sure
-
Strong all day long ! Bullish af
-
-
-
Protagonist therapeutics CFO sells over $630k in company stock
news.google.com • -
PTGX Shares Experience Surge in Value
news.google.com • -
Protagonist Therapeutics director Waddill sells $360,000 in stock
news.google.com • -
H.C. Wainwright raises Protagonist Therapeutics stock with Buy rating
news.google.com • -
3 Growth Stocks No One Is Watching (But They Should Be)
investorplace.com • -
The 3 Best Biotech Stocks to Buy in June 2024
investorplace.com •